Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism Peter Henneman, Frank G. Schaap, Louis M. Havekes, Patrick C.N. Rensen, Rune R. Frants, Arie van Tol, Hiroaki Hattori, August H.M. Smelt, Ko Willems van Dijk Atherosclerosis Volume 193, Issue 1, Pages 129-134 (July 2007) DOI: 10.1016/j.atherosclerosis.2006.05.030 Copyright © 2006 Elsevier Ireland Ltd Terms and Conditions
Fig. 1 Association between the APOA5 S19W and APOA5 −1131T>C polymorphisms and plasma apoAV level in HTG patients. ApoAV concentration is expressed as mean±S.E.M. Data are shown for all individuals characterized for the parameters involved. Differences between non-carriers and carriers of the rare variants were evaluated with Mann–Whitney analysis. *P<0.05 as compared with S19W 11/−1131 T>C 11; S19W 11/−1131 T>C 12; S19W 11/−1131 T>C 22. †Haplotype definitions as described by others [6,12,26,28]. Atherosclerosis 2007 193, 129-134DOI: (10.1016/j.atherosclerosis.2006.05.030) Copyright © 2006 Elsevier Ireland Ltd Terms and Conditions
Fig. 2 Association between the APOA5 S19W and APOA5 −1131T>C polymorphisms and serum TG level in HTG patients. Triglyceride concentration is expressed as mean±S.E.M. Data are shown for all individuals characterized for the parameters involved. Differences between non-carriers and carriers of the rare variants were evaluated with Mann–Whitney analysis. †Haplotype definitions as described previously [6,12,26,28]. Atherosclerosis 2007 193, 129-134DOI: (10.1016/j.atherosclerosis.2006.05.030) Copyright © 2006 Elsevier Ireland Ltd Terms and Conditions
Fig. 3 Association between the serum TG concentration and plasma apoAV concentration in HTG patients. The HTG population was divided in quartiles based on TG concentration. ApoAV levels are expressed as mean±S.E.M. Data are shown for all individuals characterized for the parameters involved. Differences between groups were evaluated with Mann–Whitney analysis. Significant differences are expressed as: *P<0.05; **P<0.01; ***P<0.001. Atherosclerosis 2007 193, 129-134DOI: (10.1016/j.atherosclerosis.2006.05.030) Copyright © 2006 Elsevier Ireland Ltd Terms and Conditions